The mid-stage study evaluates the efficacy of givastomig as a first-line treatment for patients with metastatic gastric cancer who do not overexpress the HER2 protein. By integrating the drug with standard chemotherapy and the immunotherapy nivolumab, NovaBridge aims to establish a more effective therapeutic regimen for this difficult-to-treat patient population.

Clinical Foundations and Market Outlook

The decision to advance the program follows encouraging data from a Phase 1b study. According to the company, that trial demonstrated several key clinical benchmarks:

• A 75% objective response rate among participants.
• A median progression-free survival of 16.9 months.
• A favorable overall safety and tolerability profile.

NovaBridge is targeting a rapidly expanding oncology segment, estimating the global market for gastric cancer treatments will reach $12 billion by 2030. The current Phase 2 study is designed to confirm whether the high response rates seen in early testing can be replicated in a larger, more diverse patient group.